Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13148426 | 0.81 | ADORA2A (0.55) | ADORA2AADORA1ADORA3ADORA2BHTT | |
| SCHEMBL26892481 | 0.81 | ADORA2A (0.54) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL14009584 | 0.81 | ADORA2A (0.54) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL30487823 | 0.80 | ADORA2A (0.50) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL15904214 | 0.80 | ADORA2A (0.50) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL28328124 | 0.79 | ADORA2A (0.50) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL2462672 | 0.77 | KDM4E (0.59) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL28870957 | 0.76 | HTT (0.62) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL5022217 | 0.74 | MAPT (0.56) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL27661572 | 0.74 | ADORA2A (0.61) | ADORA2AADORA1ADORA3ADORA2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552909-B1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2015-03-11 | — | — | EP | disclosed |
| CN-102892761-B | 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists | PALOBIOFARMA SL | 2015-02-04 | — | — | CN | disclosed |
| US-8796284-B2 | 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2014-08-05 | — | — | US | disclosed |
| US-8796284-B2 | 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2014-08-05 | — | — | US | disclosed |
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | disclosed |
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | disclosed |
| WO-2011121418-A1 | 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2011-10-06 | — | — | WO | disclosed |
| EP-1888565-B1 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL SA (ES) | 2011-03-23 | — | — | EP | disclosed |
| US-20080275064-A1 | Substituted Pyrimidines as Adenosine Receptor Antagonists | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| US-20080275064-A1 | Substituted Pyrimidines as Adenosine Receptor Antagonists | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| US-20080275064-A1 | Substituted Pyrimidines as Adenosine Receptor Antagonists | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| EP-1888565-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006110884-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA3 3/4885 |
| US-20080275064-A1 | Substituted Pyrimidines as Adenosine Receptor Antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.